UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 331

Sortiert nach

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531

Journal of clinical oncology, 2017-08, Vol.35 (23), p.2674-2682

2017

Volltextzugriff (PDF)

Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531

Journal of clinical oncology, 2021-10, Vol.39 (28), p.3149-3160

2021

Volltextzugriff (PDF)

Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group

Blood, 2013-05, Vol.121 (18), p.3573-3577

2013

Volltextzugriff (PDF)

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia

Leukemia, 2019-08, Vol.33 (8), p.1934-1943

2019

Volltextzugriff (PDF)

Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization

Clinical cancer research, 2014-02, Vol.20 (3), p.754-763

2014

Volltextzugriff (PDF)

Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

Cancer research (Chicago, Ill.), 2016-04, Vol.76 (8), p.2197-2205

2016

Volltextzugriff (PDF)

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial

Blood, 2017-06, Vol.129 (25), p.3304-3313

2017

Volltextzugriff (PDF)

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971

Blood, 2011-12, Vol.118 (26), p.6752-6759

2011

Volltextzugriff (PDF)

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report

Blood, 2014-10, Vol.124 (15), p.2400-2407

2014

Volltextzugriff (PDF)

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Clinical cancer research, 2016-04, Vol.22 (8), p.1951-1957

2016

Volltextzugriff (PDF)

Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia

Nature communications, 2022-09, Vol.13 (1), p.5487-5487, Article 5487

2022

Volltextzugriff (PDF)

Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia

Pediatric blood & cancer, 2013-06, Vol.60 (6), p.964-971

2013

Volltextzugriff (PDF)

Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group

Pediatric blood & cancer, 2011-08, Vol.57 (2), p.204-209

2011

Volltextzugriff (PDF)

Valosin‐containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group

Proteomics. Clinical applications, 2023-11, Vol.17 (6), p.e2200109-n/a

2023

Volltextzugriff (PDF)

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531

Haematologica (Roma), 2017-12, Vol.102 (12), p.2058

2017

Volltextzugriff (PDF)

Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group

Haematologica (Roma), 2012-11, Vol.97 (11), p.1770-1773

2012

Volltextzugriff (PDF)

Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial

Cancers, 2024-04, Vol.16 (8), p.1448

2024

Volltextzugriff (PDF)

Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group

International journal of cancer, 2016-11, Vol.139 (9), p.1930-1935

2016

Volltextzugriff (PDF)

Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis

Blood, 2003-06, Vol.101 (11), p.4298-4300

2003

Volltextzugriff (PDF)

WT1 Synonymous Single Nucleotide Polymorphism rs16754 Correlates With Higher mRNA Expression and Predicts Significantly Improved Outcome in Favorable-Risk Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group

Journal of clinical oncology, 2011-02, Vol.29 (6), p.704-711

2011

Volltextzugriff (PDF)

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531

Journal of clinical oncology, 2014-09, Vol.32 (27), p.3021-3032

2014

Volltextzugriff (PDF)

Increased Age at Diagnosis Has a Significantly Negative Effect on Outcome in Children With Down Syndrome and Acute Myeloid Leukemia: A Report From the Children’s Cancer Group Study 2891

Journal of clinical oncology, 2003-09, Vol.21 (18), p.3415-3422

2003

Volltextzugriff (PDF)

Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group

Haematologica (Roma), 2017-09, Vol.102 (9), p.e340

2017

Volltextzugriff (PDF)

1 – 25 von 331

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(324)
Mit Volltextzugriff
(303)

Publikationsform

Sprache

Englisch
(331)
Japanisch
(25)

Erscheinungsjahr

n.n

Thema

Science & Technology
(141)
Life Sciences & Biomedicine
(139)
Humans
(137)
Child
(111)
Oncology
(91)
Male
(86)
Female
(84)
Child, Preschool
(80)
Hematology
(79)
Infant
(76)
Adolescent
(72)
Pediatrics
(62)
Young Adult
(46)
Leukemia, Myeloid, Acute - Genetics
(45)
Acute Myeloid Leukemia
(44)
Leukemia, Myeloid, Acute - Drug Therapy
(43)
Prognosis
(42)
Treatment Outcome
(35)
Biological And Medical Sciences
(34)
Medical Sciences
(34)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531

Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531

Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia

Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization

Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia

Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG

Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group

Valosin‐containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531

Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group

Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial

Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group

Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis

WT1 Synonymous Single Nucleotide Polymorphism rs16754 Correlates With Higher mRNA Expression and Predicts Significantly Improved Outcome in Favorable-Risk Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531

Increased Age at Diagnosis Has a Significantly Negative Effect on Outcome in Children With Down Syndrome and Acute Myeloid Leukemia: A Report From the Children’s Cancer Group Study 2891

Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions

Suchergebnisse filtern